Landay, A, Reither, K, Katsoulis, L, Beattie, T, Gardiner, N, Lenz, N, Said, K, Mfinanga, E, Pohl, C, Fielding, KL, Jeffery, H, Kagina, BM, Hughes, EJ, Scriba, TJ, Hanekom, WA, Hoff, ST, Bang, P, Kromann, I, Daubenberger, C, Andersen, P and Churchyard, GJ (2015). Data from: Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ Lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial. [Data Collection]. Dryad. https://doi.org/10.5061/dryad.r61r8